{"doi":"10.1080/03007995.2017.1310091","title":"Evaluating the costs of glycemic response with canagliflozin versus dapagliflozin and empagliflozin as add-on to metformin in patients with type 2 diabetes mellitus in the United Arab Emirates","abstract":null,"journal":"Current Medical Research and Opinion","year":2017,"id":668138,"datarank":0.24141568686511508,"base_score":1.6094379124341003,"endowment":1.6094379124341003,"self_citation_contribution":0.24141568686511508,"citation_network_contribution":0.0,"self_endowment_contribution":0.24141568686511508,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":4,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1744742,"name":"Anders T. Buchholt","orcid":null,"position":1,"is_corresponding":false},{"id":1744743,"name":"Antoine C. El Khoury","orcid":null,"position":2,"is_corresponding":false},{"id":1526224,"name":"Ahmed Kamal","orcid":"0000-0002-4107-1775","position":3,"is_corresponding":false},{"id":1744744,"name":"Vanessa Taieb","orcid":null,"position":4,"is_corresponding":false},{"id":1744740,"name":"Agata Schubert","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Evaluating the costs of glycemic response with canagliflozin versus dapagliflozin and empagliflozin as add-on to metformin in patients with type 2 diabetes mellitus in the United Arab Emirates","abstract":"OBJECTIVE: This study evaluates the cost of achieving glycemic control with three sodium glucose co-transporter 2 (SGLT2) inhibitors, canagliflozin, dapagliflozin, and empagliflozin, in patients with type 2 diabetes mellitus (T2DM) from the payer perspective in the United Arab Emirates (UAE). METHODS: A systematic literature review identified randomized controlled trials of antihyperglycemic agents as add-on to metformin in patients with T2DM of 26 ± 4 weeks in duration, published by 10 September 2014. A Bayesian network-meta analysis (NMA) compared HbA1c changes with canagliflozin 100 and 300 mg versus dapagliflozin 10 mg and empagliflozin 10 and 25 mg. The cost associated with a 1% placebo-adjusted HbA1c reduction with each SGLT2 inhibitor as add-on to metformin was calculated based on NMA results and UAE drug costs. RESULTS: In the NMA, canagliflozin 100 and 300 mg were associated with HbA1c reductions (-0.67% and -0.79%) compared with dapagliflozin 10 mg (-0.41%) and empagliflozin 10 and 25 mg (-0.57% and -0.64%). Probabilities of canagliflozin 100 mg performing better were 79%, 60%, and 53% versus dapagliflozin 10 mg and empagliflozin 10 and 25 mg, respectively; probabilities for canagliflozin 300 mg performing better were 88%, 72%, and 65%, respectively. The cost per 1%-point reduction in HbA1c was projected to be lower with canagliflozin 100 and 300 mg ($448 and $422) compared with dapagliflozin 10 mg ($785) and empagliflozin 10 and 25 mg ($527 and $563). CONCLUSIONS: Canagliflozin may provide a greater glycemic response at a lower effective cost than dapagliflozin or empagliflozin for patients with T2DM inadequately controlled with metformin from the payer perspective in the UAE.","is_dataset_classified":null,"base_score":1.6094379124341003,"endowment":1.6094379124341003,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"28323512","pmcid":null,"openalex_id":"https://openalex.org/W2600856845","authors":[],"funders":[{"funder_name":"Janssen Pharmaceutica NV","grant_id":"","title":null}],"total_grants":1,"fwci":0.4684,"citation_percentile":0.64513438,"influential_citations":0,"citation_trend":[{"year":2018,"count":3},{"year":2021,"count":1}],"oa_status":"closed","license":null,"oa_locations":[{"url":"https://www.tandfonline.com/doi/pdf/10.1080/03007995.2017.1310091","host_type":"publisher"},{"url":"https://doi.org/10.1080/03007995.2017.1310091","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/28323512","host_type":"repository"}],"fields_of_study":["Diabetes Treatment and Management","Diabetes Management and Research","Pancreatic function and diabetes"],"mesh_terms":["Canagliflozin","Sodium-Glucose Transporter 2 Inhibitors","Bayes Theorem","Benzhydryl Compounds","Blood Glucose","Diabetes Mellitus, Type 2","Glucosides","Humans","Hypoglycemic Agents","Metformin","United Arab Emirates","Randomized Controlled Trials as Topic"],"keywords":["Dapagliflozin","Empagliflozin","Canagliflozin","Medicine","Metformin","Glycemic","Type 2 diabetes","Diabetes mellitus","Type 2 Diabetes Mellitus","Internal medicine","Urology","Pharmacology","Endocrinology","United Arab Emirates","Comparative Effectiveness","Network Meta-analysis","Sodium Glucose Co-transporter 2 (Sglt2) Inhibitors"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-13T20:17:03.237456Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}